Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters











Database
Language
Publication year range
1.
BMC Med Res Methodol ; 23(1): 183, 2023 08 11.
Article in English | MEDLINE | ID: mdl-37568109

ABSTRACT

BACKGROUND: The non-inferiority test is a reasonable approach to assessing a new treatment in a three-arm trial. The three-arm trial consists of a placebo, reference, and an experimental treatment. The non-inferiority is often measured by the mean differences between the experimental and the placebo groups relative to the mean differences between the reference and the placebo groups. METHODS: To cope with possible estimation distortion due to the allowance of heteroskedasticity, we adjust the measurement of non-inferiority by the incorporation of coefficient of variation (CV) of the experimental, the reference and the placebo groups. In this research, we propose a generalized [Formula: see text]-value based method (GPV-based method) to facilitate non-inferiority tests for the means with unknown coefficient of variation in a three-arm trial. RESULTS: The simulation results show that the GPV-based method can not only adequately control type I error rate at nominal level better but also provide power higher than those from Delta method and the empirical bootstrap method, which verifies the feasibility of our adjustment. CONCLUSIONS: We revise the measurement of non-inferiority by deducting the CV of each kind of treatment from the average effect of trials. CVs are included in the non-inferiority explicitly to help prevent possible estimating distortion if heteroskedasticity is allowed. Through the simulation study, the performance of GPV-based method for facilitating non-inferiority tests for the means with unknown CV in a three-arm trial is better than those from empirical bootstrap method and Delta method for small, medium and large sample sizes. Hence, the GPV-based method is recommended to be used to conduct the non-inferiority test for the means with unknown CV in a three-arm trial. The GPV-based method still performs well in non-normality cases.


Subject(s)
Research Design , Humans , Computer Simulation , Sample Size
2.
PLoS One ; 15(6): e0234432, 2020.
Article in English | MEDLINE | ID: mdl-32516350

ABSTRACT

The fraction retention non-inferiority hypothesis is often measured for the ratio of the effects of a new treatment to those of the control in medical research. However, the fraction retention non-inferiority test that the new treatment maintains the efficacy of control can be affected by the nuisance parameters. Herein, a heuristic procedure for testing the fraction retention non-inferiority hypothesis is proposed based on the generalized p-value (GPV) under normality assumption and heteroskedasticity. Through the simulation study, it is demonstrated that, the performance of the GPV-based method not only adequately controls the type I error rate at the nominal level but also is uniformly more powerful than the ratio test, Rothmann's and Wang's tests, the comparable extant methods. Finally, we illustrate the proposed method by employing a real example.


Subject(s)
Data Interpretation, Statistical , Drug Development/methods , Models, Statistical , Research Design , Treatment Outcome , Antimetabolites, Antineoplastic/therapeutic use , Capecitabine/therapeutic use , Computer Simulation , Equivalence Trials as Topic , Humans , Neoplasms/drug therapy
3.
Stat Med ; 28(25): 3108-23, 2009 Nov 10.
Article in English | MEDLINE | ID: mdl-19691022

ABSTRACT

Receiver operating characteristic (ROC) curves can be used to assess the accuracy of tests measured on ordinal or continuous scales. The most commonly used measure for the overall diagnostic accuracy of diagnostic tests is the area under the ROC curve (AUC). A gold standard (GS) test on the true disease status is required to estimate the AUC. However, a GS test may sometimes be too expensive or infeasible. Therefore, in many medical research studies, the true disease status of the subjects may remain unknown. Under the normality assumption on test results from each disease group of subjects, using the expectation-maximization (EM) algorithm in conjunction with a bootstrap method, we propose a maximum likelihood-based procedure for the construction of confidence intervals for the difference in paired AUCs in the absence of a GS test. Simulation results show that the proposed interval estimation procedure yields satisfactory coverage probabilities and interval lengths. The proposed method is illustrated with two examples.


Subject(s)
Area Under Curve , Diagnostic Tests, Routine/methods , ROC Curve , Reproducibility of Results , Biomarkers, Tumor/blood , Case-Control Studies , Computer Simulation , Confidence Intervals , Coronary Artery Disease/diagnosis , Humans , Magnetic Resonance Angiography/standards , Pancreatic Neoplasms/blood
SELECTION OF CITATIONS
SEARCH DETAIL